Calistoga: Delta force

Calistoga Pharmaceuticals Inc. was formed in 2006 to pick up an early stage research program from Icos Corp. focused on specific inhibitors of the p110 delta isoform of phosphoinositide 3-kinase. The belief is that isoform-specific inhibition could reduce the side effects associated with pan-PI3K inhibitors while

Read the full 461 word article

How to gain access

Continue reading with a
two-week free trial.